ACELYRINSLRN
SLRN
About: Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
Employees: 130
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
17% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 36
9% more funds holding
Funds holding: 112 [Q2] → 122 (+10) [Q3]
8% more capital invested
Capital invested by funds: $401M [Q2] → $434M (+$33.8M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
3.47% less ownership
Funds ownership: 91.73% [Q2] → 88.26% (-3.47%) [Q3]
43% less call options, than puts
Call options by funds: $154K | Put options by funds: $272K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
52%
upside
Avg. target
$7.33
270%
upside
High target
$13
557%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Citigroup Samantha Semenkow 20% 1-year accuracy 3 / 15 met price target | 52%upside $3 | Neutral Maintained | 7 Jan 2025 |
HC Wainwright & Co. Emily Bodnar 16% 1-year accuracy 24 / 151 met price target | 203%upside $6 | Neutral Maintained | 7 Jan 2025 |
Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target | 557%upside $13 | Overweight Maintained | 11 Dec 2024 |
Financial journalist opinion
Based on 3 articles about SLRN published over the past 30 days
Negative
Benzinga
3 weeks ago
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Neutral
GlobeNewsWire
3 weeks ago
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
Neutral
GlobeNewsWire
4 weeks ago
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here.
Neutral
GlobeNewsWire
1 month ago
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance
Neutral
Seeking Alpha
2 months ago
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript
Acelyrin, Inc. (NASDAQ:SLRN ) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Shephard Mpofu - Chief Medical Officer Conference Call Participants Tyler Van Buren - TD Cowen Emily Bodnar - H.C. Wainwright Vikram Purohit - Morgan Stanley Samantha Semenkow - Citi Operator Good afternoon, and welcome to the Acelyrin, Inc. Third Quarter 2024 Financial Results and Company Update Conference Call.
Neutral
GlobeNewsWire
2 months ago
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024
Neutral
GlobeNewsWire
2 months ago
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates.
Positive
Seeking Alpha
4 months ago
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and additional phase 2 data by the end of 2024, potentially boosting shareholder value. Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events compared to other anti-IGF-1R therapies.
Neutral
GlobeNewsWire
4 months ago
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company's global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa (HS) patients will be shared as a late-breaking oral presentation at the 2024 European Academy of Dermatology and Venereology taking place September 25-28, 2024 in Amsterdam, Netherlands. Presentation details are as follows:
Neutral
GlobeNewsWire
5 months ago
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences:
Charts implemented using Lightweight Charts™